Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
Date:11/9/2009

edically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under Special Protocol Assessment (SPA), pending commencement by year-end. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and Keryx is in the process of finalizing the U.S. Phase 3 program for Zerenex in consultation with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to complete cost-effective clinical trials or meet the projected development timelines for the drug candidates in our
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
3. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
4. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
5. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
6. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
7. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
9. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... plc (LSE: SHP, NASDAQ: SHPG ) announces that it ... the announced tender offer for all of the outstanding shares of ... the waiver, the transaction is no longer conditional on OFT approval, ... 2014 following the currently scheduled expiration time, subject to the satisfaction ...
(Date:1/15/2014)... Medical is very pleased to announce the appointment of Mr. ... Officer.  Mark was promoted from his current role of Chief ... facilities in Massachusetts , Mississippi ... in 2012 with 20+ years of broad-based operations, sales, engineering ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
(Date:4/22/2014)... Health clinics that can provide primary care for ... both hospitals and insurance companies while improving patient ... hospital admissions suggests that health clinics that avoid ... save money by lowering hospital admission rates and ... of economics, Penn State Altoona. , The ...
(Date:4/22/2014)... cancers are small cell lung cancers (SCLC), which ... However, researchers at Virginia Commonwealth University Massey Cancer ... leading to this resistance that may lead to ... mediating B-cell lymphoma 2 (Bcl-2) family proteins, which ... their function, this family of proteins can trigger ...
(Date:4/22/2014)... Bethesda, MD, April 22, 2014: The Association for ... The Journal of Molecular Diagnostics on ... the baccalaureate and master,s levels of education. The ... (MLS) Curriculum Task Force of the AMP Training ... the critical need of educating future medical laboratory ...
(Date:4/22/2014)... Working with mice and rabbits, Johns Hopkins scientists have ... and breakdown, successfully preventing the development of atherosclerosis, the ... number-one cause of death among humans. The condition develops ... renders them stiff, narrowed and hardened, greatly reducing their ... and the brain. , In a series of experiments, ...
(Date:4/22/2014)... . , Reactive ... mode of action is complex: In low concentrations they ... at high concentrations they can cause "oxidative stress", which ... signaling unfolds in single cells and organelles in real-time, ... by the teams of LMU Professor Martin Kerschensteiner and ...
Breaking Medicine News(10 mins):Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:Neuroimaging: Live from inside the cell 2
... than in for-profit residences, review finds , WEDNESDAY, Aug. ... care than for-profit facilities, say Canadian researchers who reviewed ... , Forty studies found that non-profit nursing homes provided ... for-profit homes delivered better care. The remaining studies had ...
... , , FRIENDSWOOD, Texas, Aug. ... develops, manages and owns faith-based senior living facilities, today announced the ... development of a new senior living facility in the Houston, Texas ... $10 million senior living facility in Katy, Texas, should be available ...
... , , , NASHVILLE, ... payment cycle management solutions, today announced the implementation of its ... Group. The Sentinel Group, a recognized leader in healthcare fraud ... 5, 2009. , , The Sentinel ...
... NANJING, China, Aug. 5 /PRNewswire-Asia/ -- ... manufacturer and supplier of branded generic and,innovative anti-cancer pharmaceuticals ... 2009 second quarter results on Monday, August 17, 2009,after ... executive,officer, Jinsheng Ren, and chief financial officer, Frank Zhigang ...
... INDIANAPOLIS, Aug. 5 In the midst of the down economy, ... worse - forcing them to make difficult sacrifices to afford medications ... On Aug. 1, 2009, Lilly USA adjusted the income ... enrollment of eligible patients with incomes at or less than 300 ...
... , HACKENSACK, N.J., Aug 5 ReGen Biologics, a ... regarding its Menaflex collagen meniscus implant that were made in a ... party unaffiliated with the company. ReGen was unaware of ... on the Internet. The statements made in the release do ...
Cached Medicine News:Health News:Not-For-Profit Nursing Homes Fare Better in Studies 2Health News:TrinityCare Senior Living Announces Further Expansion in Houston Area 2Health News:TrinityCare Senior Living Announces Further Expansion in Houston Area 3Health News:Emdeon Closes The Sentinel Group Acquisition, Implements First Customer in Less than 30 Days 2Health News:Emdeon Closes The Sentinel Group Acquisition, Implements First Customer in Less than 30 Days 3Health News:Emdeon Closes The Sentinel Group Acquisition, Implements First Customer in Less than 30 Days 4Health News:Simcere Pharmaceutical Group to Announce 2009 Second Quarter Earnings on Monday, August 17, 2009 2Health News:Lilly Broadens Income Eligibility for Patient Assistance Programs 2Health News:Lilly Broadens Income Eligibility for Patient Assistance Programs 3Health News:ReGen Biologics Clarifies Recent Press about the Menaflex Device 2
Acetate Plate Sealers 100/Box...
... Microseal 'B' seals provide an adhesive-based sealing ... The aggressive adhesive layer ensures secure sample ... and tight sealing during thermal cycling when ... lid. The perforated end-tabs can be removed ...
TD silicone foam compression pad. Use with plates sealed with TDX or OptiTape....
Inquire...
Medicine Products: